Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass
| العنوان: | Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass |
|---|---|
| المؤلفون: | Karin Sundfeldt, Karolina Partheen, Björg Kristjansdottir |
| المصدر: | Journal of Gynecologic Oncology |
| بيانات النشر: | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy, 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Oncology, endocrine system, medicine.medical_specialty, Population, Human epididymis protein 4, Ovarian cancer, Internal medicine, Medicine, Epithelial ovarian cancer, CA-125, Stage (cooking), education, Gynecology, education.field_of_study, Ovarian cyst, business.industry, Obstetrics and Gynecology, General Medicine, Risk of ovarian malignancy algorithm, medicine.disease, Cohort, Cystic ovarian mass, Original Article, Cutoff point, business |
| الوصف: | Objective Women presenting with a large or complex ovarian cyst are referred to extensive surgical staging to ensure the correct diagnosis and treatment of a possible epithelial ovarian cancer. We hypothesized that measurement of the biomarkers HE4 and CA-125 preoperatively would improve the assignment of these patients to the correct level of care. Methods Patients diagnosed with a cystic ovarian mass and scheduled for an operation at our center of excellence for ovarian cancer surgery from 2001 to 2010 were prospectively included (n=394) and plasma was collected consecutively. Cut-off for HE4 was calculated at 75% specificity (85 pM and 71.8 pM for post and premenopausal women). For CA-125, 35 U/mL cut-off was used. The study population included women with malignant (n=114), borderline (n=45), and benign (n=215) ovarian tumors. Results Receiver operator characteristic (ROC) area under the curve (AUC) in the benign versus malignant cohorts was 86.8% for CA-125 and 84.4% for HE4. Negative predictive value was 91.7% when at least one of the biomarkers was positive, with only early stage epithelial ovarian cancer showing false negative results. Sensitivity at set specificity (75%) was 87% for risk of ovarian malignancy algorithm (ROMA) in the postmenopausal cohort (cut-off point, 26.0%) and 81% in the premenopausal cohort (cut-off point, 17.3%). ROC AUC in the benign versus stage I epithelial ovarian cancer was only 72% for HE4 and 76% for CA-125. Conclusion In our study, population HE4 did not outperform CA-125. Based on our data a prospective trial with patients already diagnosed with an ovarian cyst may be conducted. |
| تدمد: | 2005-0399 2005-0380 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb82bfa9f4c1e65b9efad9d7b6d76724Test https://doi.org/10.3802/jgo.2011.22.4.244Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fb82bfa9f4c1e65b9efad9d7b6d76724 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20050399 20050380 |
|---|